

Performance

Learn more about our performance on our [Investor site](#).

Financial Performance

Three-year summary for the years ended December 31

(Millions, Except Per Share Data)

	2023	2022	2021	% Change	
				23/22	22/21
Revenues	\$58,496	\$100,330	\$81,288	(42)	23
Reported net income ^(a)	\$2,119	\$31,372	\$21,979	(93)	43
Reported diluted EPS ^(a)	\$0.37	\$5.47	\$3.85	(93)	42
Adjusted income ^(b)	\$10,501	\$37,717	\$23,196	(72)	63
Adjusted diluted EPS ^(b)	\$1.84	\$6.58	\$4.06	(72)	62
Net cash provided by operating activities	\$8,700	\$29,267	\$32,580	(70)	(10)
Cash dividends paid	\$9,247	\$8,983	\$8,729	3	3

(a) Reported net income is defined as *Net income attributable to Pfizer Inc. common shareholders* in accordance with U.S. Generally Accepted Accounting Principles (GAAP). Reported diluted earnings per share (EPS) is defined as diluted EPS attributable to Pfizer Inc. common shareholders in accordance with U.S. GAAP.

(b) Adjusted income and Adjusted diluted EPS are defined as U.S. GAAP *Net income attributable to Pfizer Inc. common shareholders* and *EPS attributable to Pfizer Inc. common shareholders—diluted* before the impact of amortization of intangible assets, certain acquisition-related items, discontinued operations and certain significant items. The Adjusted income and Adjusted diluted EPS measures are not, and should not be viewed as, substitutes for U.S. GAAP net income and diluted EPS, have no standardized meaning prescribed by U.S. GAAP and may not be comparable to the calculation of similar measures of other companies. See the *Non-GAAP Financial Measure: Adjusted Income* section of Management's Discussion and Analysis of Financial Condition and Results of Operations in Pfizer's 2023 Annual Report on Form 10-K for an explanation of how management uses these non-GAAP measures, reconciliations to the most directly comparable U.S. GAAP measures and additional information.

Detailed information on our financial and operational performance can be found in our 2023 Annual Report on Form 10-K.

Top 10 Medicines and Vaccines

Take a look at our breakdown of the top medicines and vaccines by revenue from 2023.

● **\$11,220 million**
COMIRNATY®¹

● **\$6,747 million**
ELIQUIS® (apixaban)²

● **\$6,440 million**
PREVNAR® Family³

● **\$4,753 million**
IBRANCE® (palbociclib)

● **\$3,321 million**
VYNDAQEL® Family⁴


● **\$1,703 million**
XELJANZ® (tofacitinib)

● **\$1,279 million**
PAXLOVID®
(nirmatrelvir tablets and ritonavir tablets)

● **\$1,191 million**
XTANDI® (enzalutamide)⁵

● **\$1,036 million**
INLYTA® (axitinib)

● **\$928 million**
NURTEC ODT®/VYDURA®
(rimegepant)



View the interactive graph on the [Annual Review site](#).

¹ COMIRNATY refers to, as applicable, and as authorized or approved, the Pfizer-BioNTech COVID-19 Vaccine, the Pfizer-BioNTech COVID-19 Vaccine, Bivalent (Original and Omicron BA.4/BA.5), COMIRNATY (COVID-19 Vaccine, mRNA, 2023-2024 Formula), the Pfizer-BioNTech COVID-19 Vaccine (2023-2024 Formula), COMIRNATY Original/Omicron BA.1, COMIRNATY Original/Omicron BA.4/BA.5 and COMIRNATY XBB.1.5. COMIRNATY includes direct sales and alliance revenues related to the sales of the above-mentioned vaccines.

² ELIQUIS includes alliance revenues and direct sales.

³ PREVNAR Family includes PREVNAR 20/APEXXNAR (pediatric and adult) and PREVNAR 13/PREVNAR 13 (pediatric and adult).

⁴ VYNDAQEL Family includes global revenues from VYNDAQEL, as well as revenues for VYNDAMAX in the U.S. and VYNMAC in Japan.

⁵ XTANDI represents alliance revenues.